Miao Jiang

Dr. Miao Jiang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XLXiaofen Li
Xiaofen Li
SLSili Liu
Sili Liu
LQLiping Qu
Liping Qu
YCYang Chen
Yang Chen
CYChuqiao Yuan
Chuqiao Yuan
WZWenjun Zou
Wenjun Zou

20 February 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JLJia Liu
Jia Liu
LDLiangyan Deng
Liangyan Deng
LQLiping Qu
Liping Qu
XLXiaofen Li
Xiaofen Li
TWTao Wang
Tao Wang
WZWenjun Zou
Wenjun Zou

19 March 2024 in Phytomedicine
Verified
Journal Article
Closed access
YLYan Liang
Yan Liang
FWFangjie Wang
Fangjie Wang
YSYinglian Song
Yinglian Song
CTCe Tang
Ce Tang
RWRuixia Wu
Ruixia Wu
ZWZhang Wang
Zhang Wang

25 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HYHongling Yan
Hongling Yan
MJMiao Jiang
Miao Jiang
FYFujin Yang
Fujin Yang
ATAnd Xueyong Tang
And Xueyong Tang
MLMao Lin
Mao Lin
DLDeming Liu
Deming Liu
The Src-homology 2 domain-containing phosphatase 2 (SHP2), which is encoded by PTPN11, participates in many cellular signaling pathways and is closely related to various tumorigenesis. Inhibition of the abnormal activity of SHP2 by small molecules is an important part of cancer treatment. Here, three abietane diterpenoids, named compounds 1–3, were isolated from Ajuga ovalifolia var. calantha. Spectroscopic analysis was used to identify the exact structure of the compounds. The enzymatic kinetic experiment and the cellular thermal shift assay showed compound 2 selectively inhibited SHP2 activity in vitro. Molecular docking indicated compound 2 targeted the SHP2 catalytic domain. The predicted pharmacokinetic properties by SwissADME revealed that compound 2 passed the majority of the parameters of common drug discovery rules. Compound 2 restrained A549 proliferation (IC50 = 8.68 ± 0.96 μM), invasion and caused A549 cell apoptosis by inhibiting the SHP2–ERK/AKT signaling pathway. Finally, compound 2 (Ajuforrestin A) is a potent and efficacious SHP2 inhibitor and may be a promising compound for human lung epithelial cancer treatment.

17 July 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YSYinglian Song
Yinglian Song
YLYan Liang
Yan Liang
RZRong Zeng
Rong Zeng
RLRan Li
Ran Li
YZYou Zhou
You Zhou
ZWZhang Wang
Zhang Wang
Introduction: Zhixue Zhentong capsules (ZXZTCs) are a Tibetan medicine preparation solely composed of Lamiophlomis rotata (Benth.) Kudo. L. rotata is the only species of the genus Laniophlomis (family Lamiaceae) that has medicinal constituents derived from the grass or root and rhizome. L. rotata is one of the most extensively used folk medicines by Tibetan, Mongolian, Naxi, and other ethnic groups in China and has been listed as a first-class endangered Tibetan medicine. The biological effects of the plant include hemostasis, analgesia, and the removal of blood stasis and swelling.Purpose: This study aimed to profile the overall metabolites of ZXZTCs and those entering the blood. Moreover, the contents of six metabolites were measured and the hemostatic, analgesic, and anti-inflammatory effects of ZXZTCs were explored.Methods: Ultra-performance liquid chromatography–tandem quadrupole time-of-flight high-resolution mass spectrometry (UPLC-Q-TOF-MS) was employed for qualitative analysis of the metabolites of ZXZTCs and those entering the blood. Six metabolites of ZXZTCs were quantitatively determined via high-performance liquid chromatography The hemostatic, analgesic, and anti-inflammatory effects of ZXZTCs were evaluated in various animal models.Results: A total of 36 metabolites of ZXZTCs were identified, including 13 iridoid glycosides, 9 flavonoids, 9 phenylethanol glycosides, 4 phenylpropanoids, and 1 other metabolite. Overall, 11 metabolites of ZXZTCs entered the blood of normal rats. Quantitative analysis of the six main metabolites, shanzhiside methyl ester, chlorogenic acid, 8-O-acetyl shanzhiside methyl ester, forsythin B, luteoloside, and verbascoside, was extensively performed. ZXZTCs exerted hemostatic effects by reducing platelet aggregation and thrombosis and shortening bleeding time. Additionally, ZXZTCs clearly had an analgesic effect, as observed through the prolongation of the latency of writhing, reduction in writhing, and increase in the pain threshold of experimental rats. Furthermore, significant anti-inflammatory effects of ZXZTCs were observed, including a reduction in capillary permeability, the inhibition of foot swelling, and a reduction in the proliferation of granulation tissue.Conclusion: Speculative identification of the overall metabolites of ZXZTCs and those entering the blood can provide a foundation for determining its biologically active constituents. The established method is simple and reproducible and can help improve the quality control level of ZXZTCs as a medicinal product. Evaluating the hemostatic, analgesic, and anti-inflammatory activities of ZXZTCs can help reveal its mechanism.

26 June 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YSYinglian Song
Yinglian Song
GSGuili Song
Guili Song
LLLame Lizhen
Lame Lizhen
YLYan Liang
Yan Liang
MHMengtian Han
Mengtian Han
ZWZhang Wang
Zhang Wang
Background: Qishiwei Zhenzhu pills (QSWZZP, Tibetan name: ) originated from Ershiwuwei Zhenzhu mother pills in the eighth century AD and are currently included in the Chinese Pharmacopoeia (2020). QSWZZP calm the mind, activate the medians, regulate qi, and harmonize the blood. QSWZZP have significant therapeutic effects in cerebral ischemia. However, QSWZZP's complex and diverse multi‐herb chemical composition has presented challenges in identifying their active ingredients, which have hitherto remained unclarified. Therefore, the present study focusses on the identification of QSWZZP's active ingredients and their therapeutic mechanisms.Aims: To analyze the distribution of QSWZZP's components in the blood and tissues for the treatment of cerebral ischemia, to identify the biomarkers after drug intervention, and to explore the mechanism of action of QSWZZP in terms of the mitochondrial apoptosis pathway.Methods: Ultra‐high performance liquid chromatography with quadrupole time‐of‐flight mass spectrometry was used for qualitative and metabolomic analysis of the distribution of QSWZZP's components in the blood and tissues. A middle cerebral artery occlusion (MCAO) rat model was used to evaluate and measure neurobehavioral changes, the ratio of cerebral infarction, the rate of apoptosis‐positive cells in the brain tissue, and the pathological changes in the cerebral cortex, hippocampus, and diencephalon. mRNA, protein, and fluorescence expressions of apoptosis‐inducing factor (AIF), P53, cytochrome C (Cyt C), apoptotic protease activating factor‐1 (APAF‐1), cleaved caspase‐8, B‐cell lymphoma‐extra‐large, and N‐myc downstream‐regulated gene family member 4 (NDRG4) were determined in the rat brain tissues via real‐time polymerase chain reaction, western blotting, and immunofluorescence. In addition, molecular docking was used to screen the active components of QSWZZP against mitochondria‐mediated apoptosis.Results: Thirty‐three new compounds were identified, including 13 triterpenoids and nine flavonoids. Among them, 15 blood‐entry, 21 urine‐entry, three brain‐entry, seven liver‐entry, and four kidney‐entry components were identified. QSWZZP significantly improved neurobehavioral abnormalities and reduced the cerebral infarction rate in the MCAO rats by significantly decreasing AIF, P53, Cyt C, APAF‐1, and cleaved caspase‐8 mRNA expressions and Cyt C and APAF‐1 protein expressions, as well as increasing NDRG4 protein expression in the rat brain tissues. Molecular docking revealed that the active ingredients of QSWZZP against mitochondrial‐mediated apoptosis were arjunic acid, cholic acid, and phyllaemblic acid.Conclusion: In this study, 45 components of QSWZZP were qualitatively analyzed, and the metabolic pathways of the related products were clarified. The potential treatment mechanism of QSWZZP may be related to the modulation of the folate biosynthesis metabolic and P53/Cyt C/APAF‐1‐mediated mitochondrial apoptosis pathways. This study may serve as the foundation for subsequent pharmacokinetic experiments and analysis of the material basis of the drug effect of QSWZZP in cerebral ischemia treatment.